Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1998 1
2002 27
2003 20
2004 44
2005 41
2006 36
2007 39
2008 54
2009 67
2010 74
2011 101
2012 115
2013 139
2014 145
2015 122
2016 140
2017 153
2018 176
2019 227
2020 258
2021 244
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,961 results
Results by year
Filters applied: . Clear all
Page 1
A genomic and epigenomic atlas of prostate cancer in Asian populations.
Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, Wang H, Yu Y, Yang C, Gao X, Hou J, Wang L, Yang B, Yang Q, Ye H, Zhou T, Lu X, Wang Y, Qu M, Yang Q, Zhang W, Shah NM, Pehrsson EC, Wang S, Wang Z, Jiang J, Zhu Y, Chen R, Chen H, Zhu F, Lian B, Li X, Zhang Y, Wang C, Wang Y, Xiao G, Jiang J, Yang Y, Liang C, Hou J, Han C, Chen M, Jiang N, Zhang D, Wu S, Yang J, Wang T, Chen Y, Cai J, Yang W, Xu J, Wang S, Gao X, Wang T, Sun Y. Li J, et al. Among authors: yang q. Nature. 2020 Apr;580(7801):93-99. doi: 10.1038/s41586-020-2135-x. Epub 2020 Mar 25. Nature. 2020. PMID: 32238934
DNA-PK deficiency potentiates cGAS-mediated antiviral innate immunity.
Sun X, Liu T, Zhao J, Xia H, Xie J, Guo Y, Zhong L, Li M, Yang Q, Peng C, Rouvet I, Belot A, Shu HB, Feng P, Zhang J. Sun X, et al. Among authors: yang q. Nat Commun. 2020 Dec 3;11(1):6182. doi: 10.1038/s41467-020-19941-0. Nat Commun. 2020. PMID: 33273464 Free PMC article.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: yang q. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.
Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Li Y, et al. Among authors: yang q. Sci Transl Med. 2019 Dec 4;11(521):eaax0428. doi: 10.1126/scitranslmed.aax0428. Sci Transl Med. 2019. PMID: 31801883 Free PMC article.
1,961 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page